PRMT9 and neoplasm: For example, PRMT5 and PRMT9 are both type II arginine methyltransferases (109), but PRMT5 has a wider range of no redundancy functions compared with PRMT9 (110) and is a perceived SL target that can selectively kill tumor cells with MTAP deficiency (111).